Literature DB >> 19450326

Diabetes: glycaemic control in type 2.

Bala Srinivasan1, Nick Taub, Kamlesh Khunti, Melanie Davies.   

Abstract

INTRODUCTION: Diabetes mellitus is now seen as a progressive disorder of glucose metabolism, affecting about 5% of the population worldwide, over 85% of whom have type 2 diabetes. Type 2 diabetes may occur with obesity, hypertension and dyslipidaemia (the metabolic syndrome), which are powerful predictors of CVD. Blood glucose levels rise progressively over time in people with type 2 diabetes regardless of treatment, causing microvascular and macrovascular complications. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical question: What are the effects of interventions in adults with type 2 diabetes? We searched: Medline, Embase, The Cochrane Library and other important databases up to October 2006 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
RESULTS: We found 69 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: combined oral drug treatment, diet, education, insulin (continuous subcutaneous infusion), insulin, intensive treatment programmes, meglitinides (nateglinide, repaglinide), metformin, monotherapy, blood glucose self-monitoring (different frequencies), and sulphonylureas (newer or older).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19450326      PMCID: PMC2907982     

Source DB:  PubMed          Journal:  BMJ Clin Evid        ISSN: 1462-3846


  65 in total

1.  Culturally competent diabetes self-management education for Mexican Americans: the Starr County border health initiative.

Authors:  Sharon A Brown; Alexandra A Garcia; Kamiar Kouzekanani; Craig L Hanis
Journal:  Diabetes Care       Date:  2002-02       Impact factor: 19.112

2.  Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control.

Authors:  Vivian Fonseca; George Grunberger; Shamita Gupta; Sharon Shen; James E Foley
Journal:  Diabetes Care       Date:  2003-06       Impact factor: 19.112

3.  Meta-analysis of randomized educational and behavioral interventions in type 2 diabetes.

Authors:  Tiffany L Gary; Jeanine M Genkinger; Eliseo Guallar; Mark Peyrot; Frederick L Brancati
Journal:  Diabetes Educ       Date:  2003 May-Jun       Impact factor: 2.140

Review 4.  Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review.

Authors:  Dawn E DeWitt; Irl B Hirsch
Journal:  JAMA       Date:  2003-05-07       Impact factor: 56.272

5.  Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes.

Authors:  Alan J Garber; Daniel S Donovan; Paresh Dandona; Simon Bruce; Jong-Soon Park
Journal:  J Clin Endocrinol Metab       Date:  2003-08       Impact factor: 5.958

6.  Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.

Authors:  Peter Gaede; Pernille Vedel; Nicolai Larsen; Gunnar V H Jensen; Hans-Henrik Parving; Oluf Pedersen
Journal:  N Engl J Med       Date:  2003-01-30       Impact factor: 91.245

7.  Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors.

Authors:  Giuseppe Derosa; Amedeo Mugellini; Leonardina Ciccarelli; Giuseppe Crescenzi; Roberto Fogari
Journal:  Clin Ther       Date:  2003-02       Impact factor: 3.393

8.  [Group versus individual education for type-2 diabetes patients].

Authors:  M R Dalmau Llorca; G García Bernal; C Aguilar Martín; A Palau Galindo
Journal:  Aten Primaria       Date:  2003-06-15       Impact factor: 1.137

9.  Efficacy and tolerability of acarbose in Asian patients with type 2 diabetes inadequately controlled with diet and sulfonylureas.

Authors:  Boniface J Lin; Huey-Peir Wu; H S Huang; Jyuhn-Huarng Juang; Jyuhn Huarng; A Sison; Dato Khalid bin Abdul Kadir; Chung-Gu Cho; Witaya Sridama
Journal:  J Diabetes Complications       Date:  2003 Jul-Aug       Impact factor: 2.852

10.  Efficacy and safety profile of glimepiride in Mexican American Patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.

Authors:  J Luis Bautista; Christine Bugos; George Dirnberger; Tracy Atherton
Journal:  Clin Ther       Date:  2003-01       Impact factor: 3.393

View more
  3 in total

1.  Type 2 diabetes in Vietnam: a cross-sectional, prevalence-based cost-of-illness study.

Authors:  Nguyen Tu Dang Le; Luyen Dinh Pham; Trung Quang Vo
Journal:  Diabetes Metab Syndr Obes       Date:  2017-08-29       Impact factor: 3.168

2.  Loss of SIRT1 in diabetes accelerates DNA damage-induced vascular calcification.

Authors:  Francesca Bartoli-Leonard; Fiona L Wilkinson; Andrew Schiro; Ferdinand Serracino Inglott; M Yvonne Alexander; Ria Weston
Journal:  Cardiovasc Res       Date:  2021-02-22       Impact factor: 10.787

3.  Association of Metformin with Susceptibility to COVID-19 in People with Type 2 Diabetes.

Authors:  Jingya Wang; Jennifer M Cooper; Krishna Gokhale; Dionisio Acosta-Mena; Samir Dhalla; Nathan Byne; Joht Singh Chandan; Astha Anand; Kelvin Okoth; Anuradhaa Subramanian; Mansoor N Bangash; Thomas Jackson; Dawit Zemedikun; Tom Taverner; Wasim Hanif; Sandip Ghosh; Parth Narendran; Konstantinos A Toulis; Abd A Tahrani; Rajendra Surenthirakumaran; Nicola J Adderley; Shamil Haroon; Kamlesh Khunti; Christopher Sainsbury; G Neil Thomas; Krishnarajah Nirantharakumar
Journal:  J Clin Endocrinol Metab       Date:  2021-04-23       Impact factor: 5.958

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.